Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q3 2023 · 10-Q
Revenue$153.88M$153.88M−13.2% vs Q3 2022 Net Income-$15.98M-$15.98MN/M vs Q3 2022 EPS Diluted-$0.29-$0.29N/M vs Q3 2022 Operating Income$8,138,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$35,725,000+160.9% Margins · derivedOperating margin5.3%+6.1 pt vs Q3 2022
Net margin-10.4%−11.4 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 8, 2023 · 39 d after period end